AST-3424

DRUG2 trials

Sponsors

Ascentawits Pharmaceuticals, Ltd, Zhejiang Hisun Pharmaceutical Co. Ltd.

Conditions

Advanced Solid TumorsHCC - Hepatocellular CarcinomaHepatocellular Carcinoma

Phase 1

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

Active, not recruitingNCT06239155

Ascentawits Pharmaceuticals, LtdAdvanced Solid Tumors, Hepatocellular Carcinoma

Start: 2019-09-03End: 2025-11-30Target: 51Updated: 2025-02-25

Phase 2

Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma

RecruitingNCT07310173

Zhejiang Hisun Pharmaceutical Co. Ltd.HCC - Hepatocellular Carcinoma

Start: 2026-01-01End: 2027-12-01Target: 75Updated: 2025-12-30

Related Papers

Safety, tolerability, pharmacokinetics and clinical activity of AST-3424, an AKR1C3-activated bis-alkylating moiety prodrug, in subjects with advanced solid tumors in China: A phase I dose-escalation study.

Journal of Clinical Oncology2024-06-011 citations